TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03858881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROJECT PERSONALITY
Description: PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR PERSONALITY PROJECT
Description: The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SHARING FEELINGS PROGRAM
Description: The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
Study: NCT03124316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving
Description: Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving
Description: Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving
Description: Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
Study: NCT03277729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given CD20 CAR T cell IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT02887248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment.
Study: NCT01241409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
Study: NCT02887248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
Study: NCT00436475

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D3 2,000 IU orally once daily
Description: Vitamin D3 2,000 IU orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D3 2,000 IU orally once daily
Description: Vitamin D3 2,000 IU orally once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium Carbonate 400 mg orally twice daily
Description: Calcium Carbonate 400 mg orally twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium Carbonate 400 mg orally twice daily
Description: Calcium Carbonate 400 mg orally twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D3-Placebo
Description: Vitamin D3-Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D3-Placebo
Description: Vitamin D3-Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium-Placebo
Description: Calcium-Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Calcium-Placebo
Description: Calcium-Placebo
Study: NCT02510963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Use Tenofovir at 24week of gestation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Use Tenofovir at 28week of gestation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Use Tenofovir at 32week of gestation
Study: NCT01241409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment A
Description: One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium: Treatment B
Description: One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
Study: NCT01547143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IST and/or alloHCT
Description: 1) Patients will be categorized by their initial serum ferritin level.~1. Mild ( ferritin\<3,000 μg/L): close observation~2. Moderate (ferritin: 3,000-10,000 μg/L):~   1. Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)~  2. continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.~3. Severe (ferritin\>10,000 μg/L):~   1. initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)~  2. continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.~      2) AlloHCT for refractory or reactivated cases.
Study: NCT00495209

Intervention type: OTHER
Intervention: Qigong
Description: EQT daily for 5 consecutive days prior to surgery.
Study: NCT02537431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: burosumab
Description: solution for subcutaneous injection
Study: NCT02298062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
Study: NCT01054092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study: NCT04168827

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completed by the parents of severe traumatized child, between 3 to 6 months after the leaving of the child out of intensive care unit
Study: NCT04023331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 67Cu-SARTATE
Description: 67Cu-labelled MeCOSar-Tyr3-octreotate
Study: NCT04454398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-GUARD
Description: COVI-GUARD (STI-1499) is a monoclonal antibody which targets the COVID-19 spike protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care as determined by the Investigator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care as determined by the Investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent
Study: NCT04111757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technolas® TENEO 317 Model 2
Description: LASIK eye surgery
Study: NCT00804401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tablets, 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Tablets, 500 mg
Study: NCT04116970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Undergo bronchoscopy with EBUS-TBNA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Transbronchial Needle Aspiration
Description: Undergo bronchoscopy with EBUS-TBNA
Study: NCT03602235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Ascorbate is in the vitamin drug class
Study: NCT03975699

Intervention type: OTHER
Intervention: Assessment of psychological repercussions of SCD
Description: Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.

Intervention type: OTHER
Intervention: Assessment of psychological repercussions of SCD
Description: Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.

Intervention type: OTHER
Intervention: Assessment of psychological repercussions of SCD
Description: Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.
Study: NCT01320332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3291
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3291
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT02708875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Meal Challenge
Description: Liquid mixed meal (300 calories - fat, carbohydrate, and protein).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Challenge
Description: Glucose drink (50g glucose)
Study: NCT01066325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique
Description: NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.~During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Instruction
Description: This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
Study: NCT03602235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan is an alkylating agent coupled to an amino acid
Study: NCT04240704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBH492
Description: Anti-CCR7 antibody-drug conjugate (ADC)
Study: NCT03575793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-\[\[5-(1,1-dimethylethyl)-1H-imidazol-4-yl\[methylene\]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-\[\[5-(1,1-dimethylethyl)-1H-imidazol-4-yl\[methylene\]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Study: NCT03250754

Intervention type: DEVICE
Intervention: Electroacupuncture
Description: Needles on the extremities were stimulated by electro-stimulation device applied by a biphasic pulse generator apparatus at a frequency of pulses alternated between 2 Hz and 100 Hz and the maximum tolerable intensity.
Study: NCT03023631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study: NCT03852264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pet dog
Description: Children will interact freely with their pet dog for 25 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pet dog
Description: Children will interact freely with their pet dog for 25 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unfamiliar dog
Description: Children will interact freely with an unfamiliar dog for 25 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unfamiliar dog
Description: Children will interact freely with an unfamiliar dog for 25 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonsocial control
Description: Children will play with age-appropriate toys/games for 25 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonsocial control
Description: Children will play with age-appropriate toys/games for 25 minutes.
Study: NCT01775072

Intervention type: GENETIC
Intervention: molecular profiling of tumors
Description: Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational next-generation profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, \& others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection \& research biopsies.

Intervention type: GENETIC
Intervention: Clinical Germline Analysis
Description: Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the ACMG list).~Part D: Germline Profiling for Individuals at Elevated Cancer Risk
Study: NCT02346396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (use at home)
Description: During 4 weeks (every week : 20 minutes / day during 5 days)
Study: NCT03357263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3114
Description: High-dose Quadrivalent influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Quadrivalent
Description: Quadrivalent influenza vaccine
Study: NCT01398670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50~The drugs would be administered subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50~The drugs would be administered subcutaneously